Alexandria Pharmaceuticals results, Fiscal year 2022
Net profit, assets, equity and cash flow for Fiscal year 2022, against the same period a year earlier, from the published financial statements. fiscal year starts in July.
Net profit117 millionEGP · +0.4% vs the same period a year earlier
Total assets875 millionEGP · +10.3% vs the same period a year earlier
Shareholders' equity630 millionEGP · +7.5% vs the same period a year earlier
Operating cash flow193 millionEGP · +93.9% vs the same period a year earlier
In short
- Alexandria Pharmaceuticals's net profit for Fiscal year 2022 was about 117 million EGP, up +0.4% from 117 million EGP in Fiscal year 2021.
- Total assets at the end of Fiscal year 2022 were about 875 million EGP, and shareholders' equity about 630 million EGP.
- Operating cash flow for Fiscal year 2022 was positive at 193 million EGP.
Key lines against the same period a year earlier
This periodFiscal year 2021Change
Net profit117 million117 million+0.4%
Gross profit461 million293 million+57.4%
Total assets875 million793 million+10.3%
Total liabilities245 million207 million+18.3%
Shareholders' equity630 million586 million+7.5%
Total liabilities and equity875 million793 million+10.3%
Operating cash flow193 million99.42 million+93.9%
Investing cash flow-26.6 million-114 million+76.6%
Financing cash flow-64.52 million-100 million+35.7%
Net change in cash102 million-114 million+188.8%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version.
Alexandria Pharmaceuticals's Q1 2027 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy